Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

@article{Lok2003LongtermSO,
  title={Long-term safety of lamivudine treatment in patients with chronic hepatitis B.},
  author={A S Lok and Ching-lung Lai and Nancy Wai Yee Leung and Guang Yao and Zhen-yu Cui and Eugene R Schiff and Jules L. Dienstag and Elizabeth Jenny Heathcote and Nancy R Little and Dorothea A Griffiths and S D Gardner and Mary Castiglia},
  journal={Gastroenterology},
  year={2003},
  volume={125 6},
  pages={1714-22}
}
BACKGROUND & AIMS Data on the long-term safety of lamivudine are limited. The aim of this analysis was to determine the incidence of hepatitis flares, hepatic decompensation, and liver-disease-related (LDR) serious adverse events (SAE) during long-term lamivudine treatment. METHODS We reviewed data on 998 patients with HBeAg-positive compensated chronic hepatitis B who received lamivudine for up to 6 years (median, 4 years) and 200 patients who received placebo for 1 year. RESULTS Hepatitis… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 292 extracted citations

Similar Papers

Loading similar papers…